New Drugs for the Treatment of Tuberculosis

Elisa H Ignatius; Kelly E Dooley

doi:10.1016/j.ccm.2019.08.001

New Drugs for the Treatment of Tuberculosis

Clin Chest Med. 2019 Dec;40(4):811-827. doi: 10.1016/j.ccm.2019.08.001.

Authors

Elisa H Ignatius¹, Kelly E Dooley²

Affiliations

¹ Department of Medicine, Johns Hopkins University School of Medicine, 1830 Building Room 450B, 1830 East Monument Street, Baltimore, MD 21287, USA.
² Department of Medicine, Center for Tuberculosis Research, Johns Hopkins University School of Medicine, 600 North Wolfe Street, Osler 527, Baltimore, MD, USA. Electronic address: kdooley1@jhmi.edu.

Abstract

Tuberculosis (TB) has now surpassed HIV as the leading infectious cause of death, and treatment success rates are declining. Multidrug-resistant TB, extensively drug-resistant TB, and even totally drug-resistant TB threaten to further destabilize disease control efforts. The second wave in TB drug development, which includes the diarylquinoline, bedaquiline, and the nitroimidazoles delamanid and pretomanid, may offer options for simpler, shorter, and potentially all-oral regimens to treat drug-resistant TB. The "third wave" of TB drug development includes numerous promising compounds, including less toxic versions of older drug classes and candidates with novel mechanisms of action.

Keywords: Bedaquiline; Delamanid; New drugs; Pharmacology; Pretomanid; Tuberculosis.

Publication types

Research Support, N.I.H., Extramural
Review

MeSH terms

Antitubercular Agents / pharmacology
Antitubercular Agents / therapeutic use*
Diarylquinolines / pharmacology
Diarylquinolines / therapeutic use*
Humans
Treatment Outcome
Tuberculosis, Multidrug-Resistant / drug therapy*

Substances

Antitubercular Agents
Diarylquinolines
bedaquiline

Abstract

Publication types

MeSH terms

Substances

Grants and funding